Nuvation Bio Company Insiders
NUVB Stock | USD 2.37 0.32 15.61% |
About 75 percent of all Nuvation Bio's insiders are aggressively buying. The analysis of the overall insider sentiment regarding Nuvation Bio suggests that quite a large number of insiders are very bullish. Nuvation Bio employs about 273 people. The company is managed by 22 executives with a total tenure of roughly 74 years, averaging almost 3.0 years of service per executive, having 12.41 employees per reported executive.
Insider Sentiment 75
Mostly Buying
Selling | Buying |
Latest Trades
2025-05-02 | Dongfang Liu | Disposed 20000 @ 2.5 | View | ||
2025-04-07 | David Hung | Acquired 300000 @ 1.62 | View | ||
2025-04-04 | David Hung | Acquired 200000 @ 1.66 | View | ||
2024-10-08 | Robert Mashal | Acquired 100000 @ 2.2 | View |
Monitoring Nuvation Bio's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nuvation Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. Nuvation Bio Management Team Effectiveness
The company has return on total asset (ROA) of (0.2333) % which means that it has lost $0.2333 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1966) %, meaning that it created substantial loss on money invested by shareholders. Nuvation Bio's management efficiency ratios could be used to measure how well Nuvation Bio manages its routine affairs as well as how well it operates its assets and liabilities. At present, Nuvation Bio's Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Other Current Assets is expected to grow to about 7.6 M, whereas Total Assets are forecasted to decline to about 464.1 M.As of July 10, 2025, Common Stock Shares Outstanding is expected to decline to about 202.3 M. The current year's Net Loss is expected to grow to about (89.1 M)
Nuvation Bio Workforce Comparison
Nuvation Bio is considered to be number one stock in number of employees category among its peers. The total workforce of Health Care industry is now estimated at about 343,227. Nuvation Bio adds roughly 273 in number of employees claiming only tiny portion of equities under Health Care industry.
Nuvation Bio Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Nuvation Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on Nuvation Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Nuvation Bio insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Stacy Markel over two weeks ago Acquisition by Stacy Markel of 10000 shares of Nuvation Bio at 1.71 subject to Rule 16b-3 | ||
Kathryn Falberg over a month ago Acquisition by Kathryn Falberg of 292983 shares of Nuvation Bio at 2.03 subject to Rule 16b-3 | ||
Liu Dongfang over two months ago Disposition of 20000 shares by Liu Dongfang of Nuvation Bio at 2.5012 subject to Rule 16b-3 | ||
David Hung over three months ago Acquisition by David Hung of 300000 shares of Nuvation Bio at 1.625 subject to Rule 16b-3 | ||
David Hung over three months ago Acquisition by David Hung of 200000 shares of Nuvation Bio at 1.6636 subject to Rule 16b-3 | ||
Mashal Robert over three months ago Acquisition by Mashal Robert of 1100 shares of Nuvation Bio at 1.6655 subject to Rule 16b-3 | ||
Cui Xiangmin over three months ago Acquisition by Cui Xiangmin of 967100 shares of Nuvation Bio subject to Rule 16b-3 | ||
Kathryn Falberg over three months ago Acquisition by Kathryn Falberg of 43000 shares of Nuvation Bio at 1.9526 subject to Rule 16b-3 |
Nuvation Bio Notable Stakeholders
A Nuvation Bio stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Nuvation Bio often face trade-offs trying to please all of them. Nuvation Bio's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Nuvation Bio's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
David Hung | President, Chief Executive Officer, Founder, Director | Profile | |
Junyuan Wang | CEO Therapeutics | Profile | |
Jennifer Fox | Chief Financial Officer | Profile | |
Moses CPA | VP Officer | Profile | |
Stephen Dang | VP Secretary | Profile | |
W Vernon | Independent Director | Profile | |
Michelle Doig | Independent Director | Profile | |
Gary Hattersley | Chief Scientific Officer | Profile | |
Moses Makunje | Principal Officer | Profile | |
Robert Bazemore | Independent Director | Profile | |
Kerry Wentworth | Chief Officer | Profile | |
Daniel Welch | Independent Chair of the Board | Profile | |
Colleen Sjogren | Chief Officer | Profile | |
David Hanley | Chief Technical Operations Officer | Profile | |
Thomas Templeman | Senior Vice President - Pharmaceutical Operations and Quality | Profile | |
Stacy Markel | Senior Vice President - Human Resources | Profile | |
Kathryn Falberg | Independent Director | Profile | |
Oleg Nodelman | Director | Profile | |
Kim Blickenstaff | Independent Director | Profile | |
Philippe Sauvage | Chief Officer | Profile | |
Sergey Yurasov | Chief Medical Officer | Profile | |
David MD | President, Founder | Profile |
About Nuvation Bio Management Performance
The success or failure of an entity such as Nuvation Bio often depends on how effective the management is. Nuvation Bio management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Nuvation management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Nuvation management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York. Nuvation Bio operates under Biotechnology classification in the United States and is traded on New York Stock Exchange. It employs 85 people.
Please note, the presentation of Nuvation Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Nuvation Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Nuvation Bio's management manipulating its earnings.
Nuvation Bio Workforce Analysis
Traditionally, organizations such as Nuvation Bio use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Nuvation Bio within its industry.Nuvation Bio Manpower Efficiency
Return on Nuvation Bio Manpower
Revenue Per Employee | 28.8K | |
Revenue Per Executive | 357.9K | |
Net Loss Per Employee | 2.1M | |
Net Loss Per Executive | 25.8M | |
Working Capital Per Employee | 1.7M | |
Working Capital Per Executive | 21.3M |
Complementary Tools for Nuvation Stock analysis
When running Nuvation Bio's price analysis, check to measure Nuvation Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nuvation Bio is operating at the current time. Most of Nuvation Bio's value examination focuses on studying past and present price action to predict the probability of Nuvation Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nuvation Bio's price. Additionally, you may evaluate how the addition of Nuvation Bio to your portfolios can decrease your overall portfolio volatility.
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Stocks Directory Find actively traded stocks across global markets | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |